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Purpose: Women with breast cancer are at increased risk for femur fracture. Contributing factors include
estrogen deﬁciency, cancer-related therapies, or direct bone involvement. This study examines fracture
subtypes in women with prior breast cancer experiencing a femur fracture.
Methods: Women age Z50 years old with a history of invasive breast cancer who experienced a femur
fracture were identiﬁed during 2005–2012. Fracture site was classiﬁed by hospital diagnosis (for hip)
and/or radiologic ﬁndings (for femoral diaphysis), with subtype classiﬁcation as pathologic, atypical or
fragility fracture. Clinical characteristics were ascertained using health plan databases and disease
registries.
Results: There were 802 women with prior breast cancer who experienced a femur fracture. The mean
age at fracture was 80.579.6 years, with most fractures (93.8%) occurring in the hip and only 6.2% in the
femoral diaphysis. However, diaphyseal fractures accounted for 23.6% of fractures in younger women
(age r65 years). Pathologic fractures comprised 9.6% of total fractures (56.0% of diaphyseal fractures)
and accounted for half the fractures in younger women. An atypical fracture pattern was seen in 1% of all
femur fractures and 16.0% of diaphyseal fractures, with prior bisphosphonate exposure in all atypical
fracture cases.
Conclusion: Most femur fractures in womenwith prior breast cancer occurred in the hip. Among younger
women and those experiencing diaphyseal fractures, a larger proportion were pathologic and some were
found to be atypical. Further studies should examine risk factors for femur fracture in womenwith breast
cancer with speciﬁc attention to fracture subtype and pharmacologic exposures.
& 2014 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Breast cancer is the leading cause of cancer among adult U.S.
women, with over 200,000 new cases estimated to have occurred
in 2013 [1]. Treatment strategies have included both endocrine
and cytotoxic therapies, with tamoxifen and aromatase inhibitors
as adjuvant therapy in postmenopausal women with hormone
receptor-positive breast cancer [2]. Treatment with aromatase
inhibitors has been associated with accelerated bone loss and
increased fracture risk [3–10], prompting greater attention
towards bone health and fracture outcomes in women with breast
cancer. Other factors contributing to greater fracture risk in
women with breast cancer include estrogen deﬁciency,
chemotherapeutic regimens, nutritional status, frailty, local cyto-
kine factors and metastatic bone disease [7,9,11–13].
Melton et al. studied 608 women with invasive breast cancer in
Olmsted County, Minnesota, and found that the overall risk of
fracture was elevated 1.8-fold, although the relative risk was only
1.2 after exclusion of pathologic and incidentally discovered
fractures [14]. This study, conducted among women with breast
cancer diagnosed in 1990–1999 followed for up to 15 years, found
that various breast cancer therapies were associated with
increased fracture risk, with the strongest associations seen for
pathologic fracture [14]. The Women's Health Initiative found a
1.5-fold increased risk of hip fracture in postmenopausal women
with breast cancer and an even higher risk among those treated
with aromatase inhibitors [15]. Compared to tamoxifen, aromatase
inhibitor therapy has been associated with a 3- to 4-fold increased
risk of hip fracture [3,4].
Of additional interest have been rare cases of atypical femur
fracture reported in women with breast cancer [16,17], described
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as transverse fractures with focal cortical hypertrophy occurring in
the femoral diaphysis with minimal trauma [18]. While atypical
fractures were initially reported in women receiving oral bispho-
sphonate therapy for osteoporosis [19], several reports have been
published describing atypical femur fractures in patients with
cancer receiving high dose intravenous bisphosphonate therapy
[17,20–22]. Within Kaiser Permanente Northern California (KPNC),
we found that up to 1 in 10 femur fractures occurring in breast
cancer patients who received high dose intravenous bisphospho-
nate therapy (e.g. for bone metastases) demonstrated an atypical
fracture pattern [16].
Collectively, these studies demonstrate that the majority of
femur fractures among female breast cancer survivors occur in the
proximal femur and are likely secondary to postmenopausal bone
loss or cancer-speciﬁc therapy. However, some fractures are
pathologic, attributable to direct skeletal metastases, and rare
cases of atypical femur fracture in women receiving bisphospho-
nate therapy have also emerged. Given the paucity of studies in
the current era examining fracture subtypes in women with breast
cancer, the primary goal of this study was to characterize fracture
site and subtype in a contemporary population of women with a
history of invasive breast cancer who experienced a fracture of the
hip or diaphyseal femur.
2. Methods
Kaiser Permanente Northern California (KPNC) is an integrated
healthcare delivery system that serves more than 3 million mem-
bers annually, of whom approximately one-ﬁfth are women aged
50 years and older. Since 1995, electronic databases have been
utilized for hospitalization and ambulatory care diagnoses, phar-
macy records, and operative and radiology reports, with digital
radiologic images since 2005. An extensive KPNC Cancer Registry
has also been maintained, with high-quality information on tumor
histology and stage of disease at initial presentation [23].
2.1. Cohort identiﬁcation and fracture site adjudication
The source cohort was derived from a large population study of
KPNC women aged 50 years and older identiﬁed as having
a principal hospital discharge diagnosis of femur fracture at a
KPNC hospital between January 1, 2005 and December 31, 2012,
based on International Classiﬁcation of Diseases, 9th edition (ICD-
9) discharge diagnoses codes 820.x, and 821.x, excluding open
fractures (ICD-9 820.1x, 820.3x, 820.9x and 821.1x), distal femur
fractures (821.2x and 821.3x) and those associated with high
energy trauma (secondary ICD-9 E800-848). Women were also
included in the source cohort if they were identiﬁed by a principal
hospital discharge diagnosis of pathologic femur fracture (733.14 and
733.15). The study cohort was then established by identifying the
subset of women with femur fracture who had a history of invasive
breast cancer diagnosed since 1988 using the KPNC Cancer Registry.
Women with in situ disease (N¼122) or missing stage (N¼14) at
initial breast cancer diagnosis were excluded. For women experien-
cing two femur fractures during the study observation period, the
ﬁrst fracture occurring after breast cancer diagnosis within the study
observation period was ascertained.
Proximal femur (hip) fractures were classiﬁed as femoral neck
(ICD-9 820.0x and 820.8x) and pertrochanteric (ICD-9 820.20 and
820.21) fractures based on principal hospital discharge diagnosis.
For diaphyseal fractures, subtrochanteric-coded (820.22) and
femoral shaft-coded (821.0x) fractures were adjudicated by an
orthopedic surgeon (CDG) after review of radiologic images to
classify subtrochanteric fractures as those occurring within 5 cm
below the lesser trochanter (based on Orthopedic Trauma
Association criteria) [24–26] and femoral shaft fractures as those
occurring below this region and up to but not including the
metaphyseal ﬂare [27]. This approach was selected due to the
large proportion of subtrochanteric-coded fractures occurring
above the lower margin of the lesser trochanter (reclassiﬁed as
pertrochanteric fracture) and periprosthetic fractures of the
femoral diaphysis (identiﬁed for exclusion) as previously described
[24]. Cases of femur fracture initially ascertained by a principal
hospital discharge diagnosis of pathologic femur fracture (ICD-9
733.14 and 733.15, N¼100) were also adjudicated by fracture site
based on radiologic ﬁndings, with review of radiologic images for
all diaphyseal fractures. Women found to have other malignancies
involving the fracture site (N¼4), those with impending fracture
(N¼6), and periprosthetic fracture (N¼3), fractures found to be
not speciﬁc to the femoral neck, pertrochanter, subtrochanter or
femoral shaft (N¼3) or adjudication uncertain (N¼4) were
excluded.
2.2. Demographic and clinical characteristics
Age and race/ethnicity were obtained using health plan demo-
graphic databases. Pharmacy dispensing records were used to
characterize use of aromatase inhibitors, tamoxifen and bispho-
sphonate drugs (both oral and intravenous) prior to femur
fracture. Dates of breast cancer diagnosis and initial cancer staging
were obtained from the KPNC Cancer Registry. Prior fracture
history (occurring after age 40 years and prior to the femur
fracture event) was obtained from outpatient and hospitalization
diagnoses of fractures involving the spine, trunk, upper and lower
extremities (ICD-9 805.0x, 805.2, 805.4, 805.6, 805.8, 807.0x, 807.2,
808.0, 808.2, 808.4x, 808.8, 809.0, 810.0x, 811.0x, 812.0x, 812.2x,
812.4x, 813.0x, 813.2x, 813.4x, 813.8x, 814.0x, 815.0x, 817.0, 818.0,
819.0, 820.0x, 820.2x, 820.8, 821.0x, 821.2x, 822.0, 823.0x, 823.2x,
823.4x, 823.8x, 824.0, 824.2, 824.4, 824.6, 824.8, 825.0, 825.2x,
827.0, 828.0, and 829.0) excluding open fractures, fractures invol-
ving spinal cord injury, fractures of the face/skull, ﬁngers and toes,
and fractures associated with high energy trauma.
2.3. Identiﬁcation of pathologic and atypical fractures
Two approaches were used to identify pathologic fractures.
First, fractures were considered pathologic if there was evidence of
biopsy-proven metastases to bone. Second, fractures were con-
sidered pathologic in patients who had a coded diagnosis of
pathologic femur fracture (ICD-9 733.14 and 733.15) or secondary
malignancy to bone (ICD-9 198.5) if there were radiologic or
clinical ﬁndings consistent with metastatic disease to the femur
(e.g. lytic, blastic or sclerotic lesions, known bone/bone marrow
involvement, or prior targeted radiation therapy).
Atypical fractures were adjudicated by an orthopedic trauma
surgeon (CDG) based on the following radiographic criteria:
presence of a primarily transverse fracture (with or without
oblique progression or a medial spike), localized periosteal or
endosteal thickening at the lateral cortex of the fracture site,
minimal or no comminution, and occurring in the presence of
minimal or no trauma [18,27]. These criteria are consistent with
the Second Task Force Report by the American Society of Bone and
Mineral Research on atypical femur fractures [18].
2.4. Statistical analyses
Differences between subgroups were compared using the chi-
square test (or Fisher exact test) for categorical variables and
Student's t-test (or Wilcoxon test) for continuous variables.
The Cochrane-Armitage test was used to examine the trend in
proportions across categories. A p-value of o0.05 was chosen as
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the criterion for statistical signiﬁcance. All analyses were con-
ducted using SAS, version 9.3 (Cary, NC).
3. Results
From the source cohort of KPNC women age Z50 years old
experiencing a femur (including pathologic femur) fracture during
2005–2012 (N¼12,891), we identiﬁed a ﬁnal femur fracture cohort
of 802 women with a prior history of invasive breast cancer,
meeting inclusion/exclusion criteria. The mean age at fracture was
80.579.6 years, with the majority of women age Z80 years and
older (61.6%) and predominantly of white race (82.2%). More than
two-thirds of the study cohort (70.3%) had localized cancer at
initial breast cancer diagnosis with a median time between breast
cancer diagnosis and fracture of 9.0 years (interquartile range 4.6–
14.2 years). The median time to fracture was 7.3 years (interquar-
tile range 3.2–12.3 years) for those who initially presented with
regional disease (lymph node or local extension) and only 3.1 years
(interquartile range 0.9–6.5) for those with metastatic disease at
initial diagnosis (po0.05 for all comparisons). Table 1 shows the
demographic and clinical characteristics of the women with prior
breast cancer at the time of fracture by age group.
Half of all femur fractures occurred in the femoral neck, with an
increasing proportion of pertrochanteric fractures among older
patients. Diaphyseal fractures accounted for only 6.2% of fractures,
but contributed to 23.6% of fractures in the youngest age group
(50–64 years old). Fig. 1 shows the stratiﬁcation of the cohort by
age, fracture site and fracture subtype, with women classiﬁed as
having a fragility fracture in the absence of adjudicated pathologic
or atypical fracture. Overall, 77 (9.6%) fractures were found to be
pathologic, with a much greater proportion of fractures that were
pathologic in the diaphyseal femur (56.0%) and among younger
women (50.0% for age 50–64 years old). Among the 77 women
with pathologic fractures, 88.3% were initially identiﬁed by a
primary or secondary ICD-9 diagnosis for pathologic fracture of
the femur (733.14 or 733.15) and an additional 7.8% were identiﬁed
by ICD-9 198.5 (metastases to bone). However, one fourth (26.9%)
of the 93 women with a principal or secondary ICD-9 diagnosis of
733.14 or 733.15 did not have evidence of metastatic disease at the
fracture site, where the designation of pathologic fracture reﬂected
osteoporosis, atypical fracture or other non-malignant processes.
We identiﬁed a total of eight atypical femur fracture cases
among women with a history of invasive breast cancer, accounting
for 16.0% of those presenting with diaphyseal femur fracture.
Three of the eight cases with atypical fracture had received high
dose intravenous bisphosphonate therapy and were previously
reported [16]. The remaining ﬁve cases with atypical fracture
received oral bisphosphonate therapy for a total duration of 4–12
years prior to fracture. Of note, there were three additional women
classiﬁed as having a pathologic fracture (based on positive bone
pathology) whose fracture pattern also appeared atypical; these
women had also previously received intravenous bisphosphonate
therapy [16].
We examined pharmacologic exposures among the subset of
women diagnosed with breast cancer on or after 1995 (N¼620)
and found that over two thirds (70.8%) received adjuvant endo-
crine therapy prior to hip or femur fracture, including 30.8% who
received tamoxifen only, 23.1% who received aromatase inhibitor
only, and 16.9% who received both tamoxifen and aromatase
inhibitor at some point during the interval between breast cancer
diagnosis and subsequent fracture. Compared to women who
received only tamoxifen therapy, women receiving any aromatase
inhibitors were signiﬁcantly younger at the time of fracture
(77.7710.6 vs 81.179.4 years old, po0.001). Even after exclusion
of pathologic and atypical fractures, there was a trend towards
greater receipt of aromatase inhibitor therapy in younger women
with fracture (46.7%, 41.3% and 33.4% for ages 50–64, 65–79 and
≥80 years, p=0.04 for trend) but not for receipt of tamoxifen-only
therapy (20.0%, 33.5% and 32.6%, respectively). Overall, 35.5% of
women received oral bisphosphonates prior to fracture (median
duration 1.3 years, interquartile range 0.3–3.9 years), including
one third (35.1%) of women with aromatase inhibitor exposure.
4. Discussion
This study of more than 800 women is one of the largest
studies to date examining femur fracture site and subtype among
contemporary women with a history of invasive breast cancer. We
found that approximately half of all ascertained fractures occurred
in the femoral neck, with a slightly smaller proportion in the
femoral pertrochanter (increasing proportionately with age as
expected) and only 6% of fractures localized to the femoral
diaphysis. These distributions were similar to those ascertained
for our health plan population of women age 60 years and older
[24,27], except for a higher proportion of diaphyseal fractures in
women with breast cancer that were more likely to be pathologic.
Overall, nearly 1 in 10 fractures were pathologic, with an even
greater proportion of pathologic fractures among younger women
age 50–64 years old (50%). We used several algorithms to identify
pathologic fracture in this study, including examination of available
bone histopathology ﬁndings for the entire cohort and clinical/
radiologic ﬁndings in women with a coded diagnosis of pathologic
fracture or metastases to bone. Our study demonstrates that patho-
logic fractures of the femur remain an important consideration in
younger womenwith breast cancer and may be increasingly relevant
in population-based studies examining fragility fracture outcomes in
early postmenopausal women with breast cancer. Melton et al. also
found that 45% of fractures occurring in premenopausal womenwith
breast cancer were pathologic, in contrast to 12% among
Table 1
Characteristics of women with a history of breast cancer experiencing femur
fracture. Numbers represent column percentages, BC¼breast cancer.
Overall
N¼802
Age 50–64 y
N¼72
Age 65–79 y
N¼236
Age Z80 y
N¼494
Race/ethnicity n,y
White 659 (82.2%) 48 (66.7%) 187 (79.2%) 424 (85.8%)
Black 27 (3.4%) 8 (11.1%) 7 (3.0%) 12 (2.4%)
Hispanic 44 (5.5%) 6 (8.3%) 13 (5.5%) 25 (5.1%)
Asian 35 (4.4%) 7 (9.7%) 14 (5.9%) 14 (2.8%)
Other/unk 37 (4.6%) 3 (4.2%) 15 (6.4%) 19 (3.9%)
Initial BC stage n,y n
Localized 564 (70.3%) 32 (44.4%) 157 (66.5%) 375 (75.9%)
Regional 212 (26.4%) 35 (48.6%) 65 (27.5%) 112 (22.7%)
Metastatic 26 (3.2%) 5 (6.9%) 14 (5.9%) 7 (1.4%)
Prior fracture 341 (42.5%) 25 (34.7%) 96 (40.7%) 220 (44.5%)
Fracture site n,y n
Femoral neck 417 (52.0%) 33 (45.8%) 139 (58.9%) 245 (49.6%)
Pertrochanter 335 (41.8%) 22 (30.6%) 79 (33.5%) 234 (47.4%)
Diaphyseal 50 (6.2%) 17 (23.6%) 18 (7.6%) 15 (3.0%)
Fracture subtype n,y n
Fragilitya 717 (89.4%) 34 (47.2%) 203 (86.0%) 480 (97.2%)
Pathologic 77 (9.6%) 36 (50.0%) 28 (11.9%) 13 (2.6%)
Atypical 8 (1.0%) 2 (2.8%) 5 (2.1%) 1 (0.2%)
Time from BC DX n n
r5 years 258 (32.2%) 32 (44.4%) 88 (37.3%) 138 (27.9%)
6–10 years 209 (26.1%) 19 (26.4%) 60 (25.4%) 130 (26.3%)
410 years 335 (41.8%) 21 (29.2%) 88 (37.3%) 226 (45.8%)
unk = unknown; DX = diagnosis; y = years.
n po0.05 when compared to age Z80 years.
y po0.05 when compared to age 65–79 years.
a Those not classiﬁed as pathologic or atypical fractures were considered as
fragility fracture.
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postmenopausal women [14]. Others have reported that up to 14% of
femoral neck fractures in patients with co-existing cancer (one-third
with breast cancer) have histopathologic evidence of bone metas-
tases [28]. Use of ICD-9 diagnosis codes for pathologic hip fracture
identiﬁed the majority of cases, although pathologic-coded fractures
do include a subset of fragility fractures due to osteoporosis where
exclusion based solely on ICD-9 codes may underestimate the burden
of fractures secondary to osteoporosis [29].
While atypical fractures accounted for only 1% of femur
fractures in this cohort, we noted with interest that 16% of
diaphyseal fractures demonstrated an atypical fracture pattern,
occurring mostly in women o80 years old. Furthermore, all
atypical fracture cases occurred in the setting of prior intravenous
or oral bisphosphonate therapy. These ﬁndings contrast with
previously reported data from our health plan, where 48% of
diaphyseal fractures (in women age Z60 years old) demonstrated
an atypical pattern, with atypical fractures accounting for more
than 1% of hip and femur fractures [27]. These differences are
likely attributable to the larger proportion of pathologic fractures
among diaphyseal fracture cases in women with breast cancer and
potential differences in race/ethnicity and bisphosphonate expo-
sure which also impact atypical fracture risk [27]. Others have
found that 17–29% of subtrochanteric and femoral shaft fractures
meet the criteria for atypical fractures among older women [19].
In the current era, nearly all cases of hormone-receptor positive
breast cancer are treated with adjuvant endocrine therapy irre-
spective of staging, with preference for aromatase inhibitors over
tamoxifen because of side effect proﬁle, survival outcome and
tumor recurrence rates [4,11]. In our study we found that women
who received aromatase inhibitors were younger at the time of hip
fracture compared to women who received tamoxifen therapy,
similar to ﬁndings from Edwards et al. [5] who demonstrated that
hip fractures associated with aromatase inhibitors tend to occur at
a younger age than otherwise expected. While we cannot exclude
the possibility that differences by endocrine therapy reﬂect
changes in breast cancer care over the past two decades (with
more recent use of aromatase inhibitors), epidemiologic data
demonstrating increased bone loss and fracture risk with aroma-
tase inhibitors [3–5,7,8] also emphasize the need to further
examine contemporary fracture risk in women with treated breast
cancer. As osteoporosis therapy is currently recommended for
patients initiating aromatase inhibitor treatment known to be at
high fracture risk [2,7,12,30] and high dose intravenous
bisphosphonate therapy remains a primary treatment modality
in the setting of skeletal metastases, long term treatment strate-
gies in women with breast cancer should also consider monitoring
for rare atypical fractures in the setting of potent antiresorptive
therapy.
Our study has some limitations. First, the true proportion of
pathologic fractures may have been higher than reported since
cases of impending fracture (which are generally pathologic) were
excluded, bone histopathology was not uniformly available [16],
and systematic review of clinical and radiologic ﬁndings was not
conducted for the entire cohort. In addition, other risk factors for
hip fracture, chemotherapeutic exposures and cancer progression
[5,12] were not examined, and pharmacologic care outside our
health system or prior to 1995 were not available for this study.
Finally, our cohort was not large enough to differentiate outcomes
by breast cancer subtype and extent of primary disease. None-
theless, this study represents one of the largest contemporary
cohorts of breast cancer survivors in whom femur fracture site and
subtype have been carefully examined. Importantly, population
studies examining hip fracture outcome in younger women with
breast cancer should note that a signiﬁcant proportion of fractures
may be pathologic rather than fragility in nature. In addition to
pathologic fractures, a small number of diaphyseal femur fractures
in bisphosphonate-treated women may be atypical. Finally, with
the increasing use of adjuvant aromatase inhibitor and bispho-
sphonate therapy, future studies should examine long term clinical
outcomes associated with optimization of bone health in women
with a history of breast cancer.
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